Therapeutic efficacy of budesonide suspension combined with poractant alfa injection for neonatal respiratory distress syndrome and its effect on serum ferritin and PAI-1 expressions.

OBJECTIVE

To investigate the therapeutic efficacy of budesonide suspension combined with poractant alfa injection for neonatal respiratory distress syndrome (NRDS) and the underlying action mechanisms.

METHODS

Sixty NRDS patients treated in Huangshi Maternity and Children's Health Hospital from May 2021 to May 2023 were enrolled and were divided into control and observation groups, which were treated with poractant alfa injection and budesonide suspension combined with poractant alfa injection, respectively.

RESULTS

After 72 hours of treatment, the total efficacy in observation group was significantly higher than control group. Compared with control treatment, in observation group the partial pressure of oxygen was significantly increased, the partial pressure of carbon dioxide, peak inspiratory pressure, respiratory rate, fraction of inspired oxygen and serum tumor necrosis factor-α, interleukin-6, high-sensitivity C-reactive protein, serum ferritin and plasminogen activator inhibitor-1 levels were significantly decreased.

CONCLUSION

Compared with poractant alfa injection, budesonide suspension combined with poractant alfa injection is more effective in treatment of NRDS. The action mechanisms may be related to its further reduction of inflammatory response and inhibition of serum ferritin and plasminogen activator inhibitor-1 expressions.